Article
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Molecular cancer therapeutics - 4 May 2022
Ferng Timothy T, Terada Daisuke, Ando Makoto, Tarver Theodore C, Chaudhary Fihr, Lin Kimberly C, Logan Aaron C, Smith Catherine C
Abstract excerpt
Small-molecule FLT3 inhibitors have recently improved clinical outcomes for patients with FLT3-mutant acute myeloid leukemia (AML) after many years of development, but resistance remains an important clinical problem. FF-10101 is the first irreversible, covalent inhibitor of FLT3 which has previo...
Topics
- Amides
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Pyrimidines
- Tumor Microenvironment
- fms-Like Tyrosine Kinase 3